Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
2000 · PubMed · 367 citations
A
Anne E.G. Lenferink
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
2.5K
Citations
21
h-index
36
i10-index
Anne E.G. Lenferink is an academic researcher from National Research Council Canada. The author has contributed to research in topics: TGF-β signaling in diseases & Monoclonal and Polyclonal Antibodies Research & HER2/EGFR in Cancer Research. The author has an h-index of 21, co-authored 67 publications.
ORCID: 0000-0001-9825-281XPapers by this author
worksErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
2001 · PubMed · 180 citations
The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin
1998 · Oncogene · 99 citations
https://doi.org/10.1038/sj.onc.1201642
The EGF domain: Requirements for binding to receptors of the ErbB family
2000 · Vitamins and hormones · 46 citations
https://doi.org/10.1016/s0083-6729(00)59005-0
Identification of the high affinity binding site of transforming growth factor-alpha (TGF-alpha) for the chicken epidermal growth factor (EGF) receptor using EGF/TGF-alpha chimeras.
1994 · Journal of Biological Chemistry · 41 citations
https://doi.org/10.1016/s0021-9258(17)37025-4
Glycoproteomic analysis of two mouse mammary cell lines during transforming growth factor (TGF)-beta induced epithelial to mesenchymal transition
2009 · Proteome Science · 41 citations
https://doi.org/10.1186/1477-5956-7-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat